Melphalan flufenamide

Drug Profile

Melphalan flufenamide

Alternative Names: J-1; Mel-flufen

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Oncopeptides
  • Class Amides; Amino acids; Antineoplastics; Fluorobenzenes
  • Mechanism of Action Alkylating agents; Caspase 3 stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 27 Oct 2016 Phase-II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Spain (IV) (EudraCT2016-000965-21)
  • 23 Mar 2015 Melphalan flufenamide receives Orphan Drug status for Multiple myeloma in European Union
  • 23 Mar 2015 Melphalan flufenamide receives Orphan Drug status for Multiple myeloma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top